Description: Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Home Page: www.cardiffoncology.com
11055 Flintkote Avenue
San Diego,
CA
92121
United States
Phone:
858 952 7570
Officers
| Name | Title |
|---|---|
| Dr. Mark Erlander Ph.D. | CEO & Director |
| Mr. James E. Levine | Chief Financial Officer |
| Dr. Fairooz F. Kabbinavar FACP, M.D. | Chief Medical Officer |
| Dr. Tod Smeal Ph.D. | Chief Scientific Officer |
| Ms. Elizabeth Anderson | VP of Finance & Administration |
| Ms. Brigitte Lindsay | Senior Vice President of Finance |
| Mr. Charles Monahan R.Ph. | Senior Vice President of Regulatory Affairs |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3451 |
| Price-to-Sales TTM: | 165.4429 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |